CellmAbs is a Portuguese biotech company focused on the discovery and development of the next generation of immunotherapies, the best in class glyco-immuno-oncology drug candidates and personalized treatments. Formally launched in June 2019, CellmAbs has already raised an important first round of investment that will allow developing a new class of immunotherapies for cancer treatments.The company is exploring IP generated at FCT NOVA. CellmAbs team is comprised of renowned scientists and international experts in the field of glycoimmunology and oncology. The company also maintains several partnerships and collaborations with national and international research centers and oncology clinical institutes.
Organic Unit: FCT NOVA / NMS|FCM